ImmunityBio, Inc.
IBRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $14,745 | $622 | $240 | $934 |
| % Growth | 2,270.6% | 159.2% | -74.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $14,745 | $622 | $240 | $934 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $190,144 | $232,366 | $248,149 | $195,958 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $168,783 | $129,620 | $102,708 | $135,256 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $886 | $681 | $0 |
| Operating Expenses | $358,927 | $362,872 | $351,538 | $331,214 |
| Operating Income | -$344,182 | -$362,250 | -$351,298 | -$330,280 |
| % Margin | -2,334.2% | -58,239.5% | -146,374.2% | -35,361.9% |
| Other Income/Exp. Net | -$69,463 | -$221,642 | -$65,988 | -$19,559 |
| Pre-Tax Income | -$413,645 | -$583,892 | -$417,286 | -$349,839 |
| Tax Expense | $0 | -$40 | $34 | $9 |
| Net Income | -$413,564 | -$583,196 | -$416,567 | -$346,790 |
| % Margin | -2,804.8% | -93,761.4% | -173,569.6% | -37,129.6% |
| EPS | -0.59 | -1.15 | -1.04 | -0.89 |
| % Growth | 48.7% | -10.6% | -16.9% | – |
| EPS Diluted | -0.62 | -1.15 | -1.04 | -0.89 |
| Weighted Avg Shares Out | 697,312 | 508,636 | 399,900 | 389,234 |
| Weighted Avg Shares Out Dil | 700,443 | 508,636 | 399,900 | 389,234 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,400 | $863 | $2,708 | $836 |
| Interest Expense | $131,658 | $86,717 | $47,145 | $14,849 |
| Depreciation & Amortization | $17,554 | $18,512 | $18,260 | $14,238 |
| EBITDA | -$264,433 | -$478,663 | -$351,881 | -$320,752 |
| % Margin | -1,793.4% | -76,955.5% | -146,617.1% | -34,341.8% |